Coya Therapeutics, Inc. (COYA): Net Income

Annual figures by period end, from SEC filings.

-$21.23M

Year ended 2025-12-31

-$21.67M

Trailing 12 months to 2026-06-30

2021-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$21.23M	n/m	2026-03-16, From 2025-01-01
2024-12-31	-$14.88M	n/m	2026-03-16, From 2024-01-01
2023-12-31	-$7.99M	n/m	2025-03-18, From 2023-01-01
2022-12-31	-$12.24M	n/m	2024-03-19, From 2022-01-01
2021-12-31	-$4.89M	n/a	2023-03-29, From 2021-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Coya Therapeutics, Inc. (COYA)	2025-12-31	-$21.23M	n/m
Aclaris Therapeutics, Inc. (ACRS)	2025-12-31	-$64.92M	n/m
Bolt Biotherapeutics, Inc. (BOLT)	2025-12-31	-$33.38M	n/m
Adagene Inc. (ADAG)	2025-12-31	-$17.61M	n/m
Roivant Sciences Ltd. (ROIV)	2026-03-31	-$299.77M	n/m
Xenon Pharmaceuticals Inc. (XENE)	2025-12-31	-$345.91M	n/m
Ovid Therapeutics Inc. (OVID)	2025-12-31	-$17.41M	n/m
Whitehawk Therapeutics, Inc. (WHWK)	2025-12-31	-$20.60M	n/m
BioAge Labs, Inc. (BIOA)	2025-12-31	-$80.61M	n/m

Compare COYA, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗